Dr. Augusto Ocano has been named the new CEO of CytoCore (Chicago). Previously, Ocano was senior vice president and managing director at CH-Werfen, S.A., a $1 billion medical research and device company. He has also served in leadership roles at pharmaceutical companies such as Group Taper, S.A., and Abbott Laboratories. He has also served on the board of directors of health care companies. CytoCore develops cancer screening systems, which it says can be used in a laboratory or at the point-of-care, to assist in the early detection of cervical, endometrial, and other cancers.